Patent denied, price of prostate cancer drug may go down
The Indian Patent Office has denied a patent to Xtandi (Enzalutamide), a steeplypriced wonder drug used in prostate cancer, on the pre-grant opposition filed by a clutch of entities, including Mumbai-based BDR Pharma, drug company Fresenius Kabi and Indian Pharmaceutical Alliance. The refusal to grant a patent paves the way for the entry of drug's generic version at a fraction of the price -at least 60-70% cheaper. At present, Japan's Astellas Pharma sells the drug in India at Rs 3.35 lakh for a pack of 112 capsules for a month's dose....